Pharmaceutical composition of polycyclic compound, preparation method therefor, and use thereof
By preparing a solid dispersion of compound (I) and using polyethylene glycol or polyvinylpyrrolidone vinyl acetate as a carrier, the problem of poor water solubility of the compound was solved, achieving rapid dissolution and high bioavailability, which is suitable for industrial production.
Patent Information
- Application Number
- PCT/CN2026/097438
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
The compound shown in formula (I) has poor water solubility. Although it is improved after being prepared as a hemicalcium salt, it still needs to be further improved to achieve better oral absorption and solubility.
Solid dispersions of compounds of formula (I) or their pharmaceutically acceptable salts are prepared by spray drying using solid dispersion carriers such as polyethylene glycol or polyvinylpyrrolidone vinyl acetate, thereby improving the solubility and bioavailability of the compounds.
It achieves rapid and uniform dissolution of active pharmaceutical ingredients, improves bioavailability, and has good stability and adaptability to industrial production.
Smart Images

Figure PCTCN2026097438-FTAPPB-I100001 
Figure PCTCN2026097438-FTAPPB-I100002 
Figure PCTCN2026097438-FTAPPB-I100003
Abstract
Description
Pharmaceutical compositions of polycyclic compounds, their preparation methods and applications Technical Field
[0001] This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a solid dispersion of a polycyclic compound, a pharmaceutical composition containing the solid dispersion, its uses, and a preparation method thereof. Background Technology
[0002] GLP-1 (glucagon-like peptide-1) is mainly synthesized and secreted by L cells located in the ileum and colon. It acts on GLP-1R (glucagon-like peptide-1 receptor), which is mainly distributed in pancreatic β and α cells, the gastrointestinal tract, the central nervous system, and the cardiovascular system. GLP-1R belongs to the glucagon receptor subfamily within the G protein-coupled receptor B cluster. Its key characteristics include a seven-transmembrane core domain and a relatively large extracellular domain.
[0003] In the central nervous system, GLP-1R agonists increase satiety, reduce food intake, alleviate nausea, and promote nerve cell survival. In other tissue systems, GLP-1R agonists also lower blood pressure, improve microvascular function, reduce inflammation, reduce gastric emptying, lower blood glucose, increase insulin sensitivity, and reduce gluconeogenesis. Therefore, GLP-1R agonists can lower blood glucose and / or promote weight loss, thereby preventing and / or treating diabetes, overweight, or obesity. Moreover, GLP-1R agonists can exert their weight-loss effect through multiple biological mechanisms.
[0004] Furthermore, there is evidence that agonistic effects on GLP-1R are also a promising strategy for the prevention and / or treatment of Alzheimer's disease (AD), liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease (MASLD)). For example, some evidence suggests that liraglutide acts directly on human hepatocytes in vitro, reducing steatosis by decreasing de novo lipogenesis (DNL) levels and increasing fatty acid oxidation. Notably, steatosis and hepatocyte swelling improved in most patients after treatment with liraglutide. Exciting experimental evidence is available in patients with non-alcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) to suggest that liraglutide has the potential to reduce lipotoxicity by improving insulin sensitivity in adipose tissue.
[0005] The compound represented by formula (I) is a polycyclic compound, as described in WO2025 / 131043A, which can be used to treat and / or prevent diseases mediated by GLP-1R: Summary of the Invention
[0006] The inventors of this disclosure have discovered through research that the compound shown in formula (I) (in its free acid form) has very poor water solubility. Although the water solubility is improved after being prepared as a hemicalcium salt (e.g., the compound shown in formula (II)), there is still a need for further improvement.
[0007] To further improve oral absorption and increase compliance, the inventors of this disclosure, through in-depth research, prepared a solid dispersion containing the compound of formula (I) or its pharmaceutically acceptable salt (e.g., the hemicalcium salt of the compound of formula (I)). This resulted in a significant improvement in the solubility of the compound of formula (I) or its pharmaceutically acceptable salt (e.g., the hemicalcium salt of the compound of formula (I)), significantly increased the dissolution of the active pharmaceutical ingredient, and improved bioavailability.
[0008] The pharmaceutical compositions and / or formulations obtained using the solid dispersion method described in this disclosure have good dissolution effects and can achieve rapid dissolution; the preferred formulations not only achieve rapid dissolution, but also have the characteristics of smaller error (i.e., smaller relative standard deviation of dissolution amount) and uniform dissolution rate.
[0009] Pharmaceutical compositions and / or formulations obtained using the solid dispersion method described in this disclosure have good stability.
[0010] Pharmaceutical compositions and / or formulations obtained using the solid dispersion method described in this disclosure can achieve better in vivo (e.g., in animals and / or humans) pharmacokinetic properties, such as superior oral absorption performance and better data stability (e.g., lower coefficient of variation) of oral absorption parameters (e.g., Cmax, AUC, AUC / D, etc.).
[0011] The solid dispersion preparation method described in this disclosure is simple, the preparation process of pharmaceutical compositions and / or formulations is smooth, and there are no stringent requirements on the instruments, equipment and operating procedures used, making it more suitable for industrial production.
[0012] In a first aspect, this disclosure provides a solid dispersion comprising an active ingredient and a solid dispersion carrier, wherein the active ingredient is a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0013] In some embodiments, the active ingredient is a hemicalcium salt of the compound shown in formula (I).
[0014] In some embodiments, the active ingredient is a hemicalcium salt of the compound shown in formula (I), i.e., the stoichiometric ratio of the compound shown in formula (I) to calcium ions is 1:0.5; or, the active ingredient is a calcium salt of the compound shown in formula (I), i.e., the stoichiometric ratio of the compound shown in formula (I) to calcium ions is 2:1.
[0015] In some embodiments, the active ingredient has the structural formula shown in formula (II).
[0016] In some embodiments, the active ingredient has the structural formula shown in formula (II').
[0017] In some embodiments, the hemicalcium salt of the compound shown in formula (I), the compound shown in formula (II), or the compound shown in formula (II') is in hydrate form.
[0018] In some embodiments, the active ingredient is in solid form; preferably, using Cu-Kα radiation, the active ingredient exists in an amorphous form.
[0019] In some implementations, Cu-Kα radiation is used, and the solid dispersion is in an amorphous form.
[0020] In some embodiments, the solid dispersion carrier is selected from polymeric carriers; preferably polyethylene glycol or polyvinylpyrrolidone vinyl acetate (also known as "copovidone" or "PVP-VA"); more preferably copovidone VA64.
[0021] In some embodiments, the active ingredient comprises 20% to 55% by weight of the solid dispersion; preferably 23% to 54%; more preferably 24% to 52% (e.g., 25% to 51%, 26% to 51%, 30% to 50%, 30% to 45%, 31% to 40%, 32% to 40%, 30% to 35%, about 33%); more preferably, the active ingredient comprises 30% to 35% by weight of the solid dispersion. Preferably, the active ingredient is a compound of formula (I).
[0022] In some embodiments, the solid dispersion carrier accounts for 40% to 80% of the weight of the solid dispersion (approximately 45% to 70%, 46% to 69%, 47% to 68%, 48% to 67%, 49% to 66.5%, 50% to 67%, approximately 65%, approximately 66%).
[0023] In some embodiments, the solid dispersion contains small amounts (e.g., less than 5%, 4%, 3%, 2%, 1.5%, 1%, or 0.5% by mass) or trace amounts of one or more processing solvents; preferably, the processing solvent is selected from one or more of methanol, ethanol, or water; more preferably, the processing solvent is selected from one or more of methanol or ethanol.
[0024] In some embodiments, the solid dispersion comprises an active ingredient and a solid dispersion carrier. The active ingredient constitutes 20% to 55% of the solid dispersion by weight; preferably 23% to 54%; more preferably 24% to 52% (e.g., 25% to 51%, 26% to 51%, 30% to 50%, 30% to 45%, 31% to 40%, 32% to 40%, 30% to 35%, about 33%); the balance being the solid dispersion carrier. Preferably, the weight percentage of the active ingredient is based on the compound represented by formula (I).
[0025] In some embodiments, the weight ratio of the active ingredient to the solid dispersion carrier in the solid dispersion is 2:1 to 1:3; preferably 2:1 to 1:2.5; more preferably 2:1 to 1:2; and even more preferably 1:1 to 1:2. Preferably, the weight of the active ingredient is in the form of the compound shown in formula (I).
[0026] In some embodiments, the particle size D of the solid dispersion 90 ≤150μm (e.g., D) 90 ≤100μm, D 90 ≤90μm, D 90 ≤80μm, D 90 ≤70μm, D 90 ≤60μm, D 90 ≤55μm, D 90 ≤50μm); preferably, the particle size D of the solid dispersion is... 90 The range is 1–100 μm (i.e., 1 μm ≤ D). 90 ≤100μm, for example, 5–90μm, 5–80μm, 5–70μm, 10–60μm, about 5μm to about 50μm, about 10μm to about 50μm, about 15μm to about 50μm, about 18μm to about 50μm, about 20μm to about 50μm).
[0027] In a second aspect, this disclosure provides a method for preparing a solid dispersion as described in the first aspect, comprising: (1) weighing: weighing the active ingredient raw material, the solid dispersion carrier and the solvent according to the composition; (2) dissolving: dissolving the active ingredient raw material and the solid dispersion carrier in the solvent; and (3) preparing the solid dispersion by spray drying.
[0028] In some embodiments, the active ingredient raw material is a hemicalcium salt of the compound shown in formula (I), the compound shown in formula (II), or crystal form I of the compound shown in formula (II'); preferably, the crystal form I, when irradiated with Cu-Kα, has a powder X-ray diffraction pattern in 2θ angles (°) with characteristic diffraction peaks at one or more of the following positions: 6.7±0.2°, 10.4±0.2°, 11.7±0.2°, 18.5±0.2°, 19.4±0.2°; or, when irradiated with Cu-Kα, its powder X-ray diffraction pattern is substantially as shown in Figure 1.
[0029] In some embodiments, the crystal form I is tested using thermogravimetric analysis (TGA), and its TGA spectrum is substantially as shown in Figure 2; or, its TGA spectrum is as shown in Figure 2.
[0030] In some embodiments, the crystal form I, tested using thermogravimetric analysis (TGA), has a weight loss percentage of 3% ± 0.5% (or 2.968%) in the range of 60°C ± 5°C to 150°C ± 5°C (or 60°C-150°C); preferably, this weight loss is the loss of water of crystallization.
[0031] In some embodiments, the crystal form I is a hydrate; preferably, the stoichiometric ratio of the compound represented by formula (I), calcium ions and water molecules is 1:0.5:1.5 (or, it can also be expressed as 2:1:3).
[0032] In some embodiments, the solvent is methanol or a mixture of methanol and ethanol, wherein the weight ratio of methanol to ethanol in the mixture is 1:4 to 1:20; preferably, the solvent is a mixture of methanol and ethanol; more preferably, the weight ratio of methanol to ethanol in the mixture is 1:5 to 1:20 (e.g., 1:6 to 1:20, 1:6 to 1:19, 1:10 to 1:19, 1:15 to 1:19, 1:19).
[0033] In some embodiments, in the preparation method, the total content (mass fraction) of the active ingredient raw material and the solid dispersion carrier in the solvent is 10% to 30%; preferably 11% to 25%; preferably 12% to 24%; preferably 13% to 23%; preferably 14% to 22%; preferably 15% to 22%; preferably 15% to 21%; preferably 15% to 20%.
[0034] In some embodiments, in the preparation method, the total content (mass fraction) of the active ingredient raw material and the solid dispersion carrier in the mixture (e.g., solution) obtained after dissolution is 10% to 30%; preferably 11% to 25%; preferably 12% to 24%; preferably 13% to 23%; preferably 14% to 22%; preferably 15% to 22%; preferably 15% to 21%; preferably 15% to 20%.
[0035] In some embodiments, the composition of the solid dispersion is as follows:
[0036] Thirdly, this disclosure provides the use of the solid dispersion as described in the first aspect in the preparation of a medicament; preferably, the medicament is a medicament as a GLP-1 receptor agonist; more preferably, the medicament is a medicament for treating diseases mediated by the GLP-1 receptor; more preferably, the medicament is a medicament for treating diabetes, overweight or obesity, liver disease (e.g., non-alcoholic fatty liver disease or fatty liver disease associated with metabolic dysfunction, non-alcoholic steatohepatitis or fatty liver disease associated with metabolic dysfunction) or Alzheimer's disease; even more preferably, the medicament is a medicament for treating type 2 diabetes.
[0037] In some embodiments, this disclosure provides a solid dispersion as described in the first aspect for use as a GLP-1 receptor agonist; preferably, this disclosure provides a solid dispersion as described in the first aspect for treating diseases mediated by the GLP-1 receptor; more preferably, this disclosure provides a solid dispersion as described in the first aspect for treating diabetes, overweight or obesity, liver disease (e.g., non-alcoholic fatty liver disease or fatty liver disease associated with metabolic dysfunction, non-alcoholic steatohepatitis or fatty hepatitis associated with metabolic dysfunction) or Alzheimer's disease; even more preferably, this disclosure provides a solid dispersion as described in the first aspect for treating type 2 diabetes.
[0038] In some embodiments, this disclosure provides a method for treating a disease by activating GLP-1 receptors, comprising administering a solid dispersion as described in the first aspect; preferably, the method comprises administering a therapeutically effective amount of the solid dispersion as described in the first aspect to a subject in need; more preferably, the disease treated by the method of this disclosure is a GLP-1 receptor-mediated disease; more preferably, the disease treated by the method of this disclosure is selected from the group consisting of diabetes, overweight or obesity, liver disease (e.g., non-alcoholic fatty liver disease or metabolically dysfunction-related fatty liver disease, non-alcoholic steatohepatitis or metabolically dysfunction-related steatohepatitis), and Alzheimer's disease; even more preferably, the diabetes is type 2 diabetes.
[0039] Fourthly, this disclosure provides a pharmaceutical composition comprising the solid dispersion as described in the first aspect.
[0040] In some embodiments, the pharmaceutical composition comprises the solid dispersion and an excipient selected from one or more fillers, lubricants, and flow aids; optionally, the excipient further comprises a disintegrant and / or a pH adjuster.
[0041] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a filler, a flow aid, and a pH adjuster as described in the first aspect.
[0042] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a pH adjuster, a filler, a lubricant, and a disintegrant as described in the first aspect.
[0043] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a pH adjuster, a filler, a flow aid, a lubricant, and a disintegrant as described in the first aspect.
[0044] In some embodiments, the solid dispersion in the pharmaceutical composition comprises 0.5% to 45% by weight of the pharmaceutical composition (e.g., 0.8% to 43%, 1% to 42%, 1% to 41%, 1% to 40%; or 0.5% to 20%, 0.8% to 15%, 1% to 11%, 1% to 10%, 1% to 9%, 4% to 9%, 5% to 9%, 5.5% to 9%, about 8.5%; or 5% to 41%, 8% to 40%, 10% to 30%, 12% to 25%, 13% to 22%, 13.3% to 20%, 0.8% to 30%, 0.8% to 25%, 1% to 25%, 1% to 20%, 1% to 15%).
[0045] In some embodiments, the filler is selected from microcrystalline cellulose, microcrystalline cellulose colloidal silica co-treated material, mannitol, lactose cellulose, starch, lactose, or pregelatinized starch; preferably, it is microcrystalline cellulose or microcrystalline cellulose colloidal silica co-treated material; preferably, the microcrystalline cellulose is microcrystalline cellulose 102, and the microcrystalline cellulose colloidal silica co-treated material is microcrystalline cellulose colloidal silica co-treated material 90.
[0046] In some embodiments, the filler in the pharmaceutical composition comprises 10% to 75% by weight of the pharmaceutical composition (e.g., 10.5% to 70%, 11% to 70%; or 25% to 70%, 31% to 50%, 31% to 45%, 31.5% to 43%, 32% to 42%, 32% to 41.5%, 32% to 40%, 32% to 39%, about 33.5%; or 10% to 60%, 11% to 57%, 11% to 55%, 15% to 35%, 17% to 30%, 18% to 28%).
[0047] In some embodiments, the flow aid is colloidal silica.
[0048] In some embodiments, the gliding agent comprises 0.5% to 7% by weight of the pharmaceutical composition (e.g., 1% to 6%, or 1% to 5.5%, or 1% to 5%, or 1.5% to 3%, or 1.5% to 2.5%).
[0049] In some embodiments, the lubricant is selected from one or more of starch, polyethylene glycol, magnesium stearate, calcium stearate, sodium benzoate, sodium lauryl sulfate, zinc stearate, sodium stearate fumarate, magnesium stearate fumarate, magnesium lauryl sulfate, sodium lauryl sulfate, or magnesium lauryl sulfate; preferably, the lubricant is selected from one or more of magnesium stearate, calcium stearate, zinc stearate, sodium stearate fumarate, or magnesium stearate fumarate; more preferably, the lubricant is magnesium stearate.
[0050] In some embodiments, the lubricant in the pharmaceutical composition is 1% to 3% by weight of the pharmaceutical composition (e.g., 1% to 2.5%, 1.2% to 2%, 1.4% to 2%, about 2%).
[0051] In some embodiments, the lubricant is divided into an internal lubricant and an external lubricant, wherein the weight ratio of the internal lubricant to the external lubricant is 1:(0.5-2); preferably 1:(1-1.5); and more preferably 1:1.
[0052] In some embodiments, the disintegrant is selected from one or more of sodium carboxymethyl starch, croscarmellose, and croscarmellose (or croscarmellose); preferably croscarmellose; more preferably croscarmellose XL.
[0053] In some embodiments, the disintegrant in the pharmaceutical composition is 0% to 35% by weight of the pharmaceutical composition (e.g., 0% to 30%, 0% to 25%, 0% to 20%; or 10% to 30%, 13% to 25%, 15% to 24%, 16% to 23%, 17% to 22%, 18% to 21%, about 20%).
[0054] In some embodiments, the disintegrant is divided into an internally added disintegrant and an externally added disintegrant, wherein the weight ratio of the internally added disintegrant to the externally added disintegrant is 1:4 to 4:1; preferably 1:3.5 to 3.5:1; more preferably 1:3 to 3:1; more preferably 1:2 to 2:1; more preferably (1 to 3):1; more preferably 3:1, 2:1 or 1:1.
[0055] In some embodiments, the pH adjuster is selected from one, two or more of sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium hydroxide, calcium hydroxide and magnesium oxide; preferably sodium bicarbonate or sodium carbonate; more preferably sodium bicarbonate; more preferably anhydrous sodium bicarbonate or hydrated sodium bicarbonate; and even more preferably anhydrous sodium bicarbonate.
[0056] In some embodiments, the pH adjuster comprises, by weight, 0% to 85% of the pharmaceutical composition (e.g., 0% to 80%, 30% to 80%; or 0% to 50%, 30% to 45%, 30% to 40%, 32% to 39%, 33% to 38%, 33% to 37%, 34% to 36%, about 35.5%; or 0% to 80%, 40% to 80%, 45% to 75%, 48% to 70%, 50% to 68%).
[0057] In some embodiments, the pharmaceutical composition comprises a solid dispersion as described in the first aspect, a filler, a flow aid and / or a lubricant, an optional disintegrant, and an optional pH adjuster, wherein:
[0058] The solid dispersion comprises, by weight, 0.5% to 45% of the pharmaceutical composition (e.g., 0.8% to 43%, 1% to 42%, 1% to 41%, 1% to 40%).
[0059] The filler comprises 10% to 75% (e.g., 10.5% to 72%, 11% to 70%) of the pharmaceutical composition by weight;
[0060] The gliding agent is present at 0.5% to 7% by weight of the pharmaceutical composition (e.g., 1% to 6%, or 1% to 5.5%, or 1% to 5%, or 1.5% to 3%, or 1.5% to 2.5%); and / or
[0061] The lubricant is 1% to 3% by weight of the pharmaceutical composition (e.g., 1% to 2.5%, 1.2% to 2%, 1.4% to 2%, about 2%); and / or
[0062] The disintegrant is present in an amount of 0% to 35% by weight of the pharmaceutical composition (e.g., 0% to 30%, 0% to 25%, 0% to 20%); and / or
[0063] The pH adjuster is 0% to 85% (e.g., 0% to 80%, 30% to 80%) of the pharmaceutical composition by weight.
[0064] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a filler, a flow aid, and optionally a pH adjuster as described in the first aspect, wherein:
[0065] The solid dispersion comprises 5% to 41% by weight of the pharmaceutical composition (e.g., 8% to 40%, 10% to 40%, 12% to 25%, 13% to 22%, 13.3% to 20%).
[0066] The filler comprises 10% to 60% by weight of the pharmaceutical composition (e.g., 11% to 57%, 11% to 55%, 15% to 35%, 17% to 30%, 18% to 28%).
[0067] The gliding agent is present at 0.5% to 7% by weight of the pharmaceutical composition (e.g., 1% to 6%, or 1% to 5.5%, or 1% to 5%, or 1.5% to 3%, or 1.5% to 2.5%); and / or
[0068] The pH adjuster is 0% to 80% by weight of the pharmaceutical composition (e.g., 40% to 80%, 45% to 75%, 48% to 70%, 50% to 68%).
[0069] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a filler, a lubricant, a disintegrant, and optionally a pH adjuster as described in the first aspect, wherein:
[0070] The solid dispersion comprises, by weight, 0.5% to 20% of the pharmaceutical composition (e.g., 0.8% to 15%, 1% to 11%, 1% to 10%, 1% to 9%, 4% to 9%, 5% to 9%, 5.5% to 9%, about 8.5%).
[0071] The filler comprises 25% to 70% by weight of the pharmaceutical composition (e.g., 31% to 50%, 31% to 45%, 31.5% to 43%, 32% to 42%, 32% to 41.5%, 32% to 40%, 32% to 39%, about 33.5%).
[0072] The lubricant is 1% to 3% by weight of the pharmaceutical composition (e.g., 1% to 2.5%, 1.2% to 2%, 1.4% to 2%, about 2%).
[0073] The disintegrant is present in an amount of 10% to 30% by weight of the pharmaceutical composition (e.g., 13% to 25%, 15% to 24%, 16% to 23%, 17% to 22%, 18% to 21%, about 20%); and / or
[0074] The pH adjuster is 0% to 50% by weight of the pharmaceutical composition (e.g., 30% to 45%, 30% to 40%, 32% to 39%, 33% to 38%, 33% to 37%, 34% to 36%, about 35.5%).
[0075] In some embodiments, the pharmaceutical composition further comprises 0% to 15% (e.g., 0% to 10%, 0% to 5%) of other excipients by weight of the pharmaceutical composition.
[0076] In some embodiments, the sum of the weight percentages of the components in the pharmaceutical composition is 100%.
[0077] In some embodiments, the pharmaceutical composition comprises a solid dispersion as described in the first aspect, a filler, a flow aid, an optional pH adjuster, and optional other excipients.
[0078] The solid dispersion comprises 5% to 41% by weight of the pharmaceutical composition (e.g., 8% to 40%, 10% to 40%, 12% to 25%, 13% to 22%, 13.3% to 20%).
[0079] The filler comprises 10% to 60% by weight of the pharmaceutical composition (e.g., 11% to 57%, 11% to 55%, 15% to 35%, 17% to 30%, 18% to 28%).
[0080] The gliding agent is present at 0.5% to 7% by weight of the pharmaceutical composition (e.g., 1% to 6%, or 1% to 5.5%, or 1% to 5%, or 1.5% to 3%, or 1.5% to 2.5%); and / or
[0081] The pH adjuster is present at 0% to 80% by weight of the pharmaceutical composition (e.g., 40% to 80%, 45% to 75%, 48% to 70%, 50% to 68%); and / or
[0082] Other excipients, by weight, constitute 0% to 15% of the pharmaceutical composition (e.g., 0% to 10%, 0% to 5%).
[0083] The sum of the weight percentages of the above components is 100%.
[0084] In some embodiments, the pharmaceutical composition comprises a solid dispersion as described in the first aspect, a filler, a lubricant, a disintegrant, an optional pH adjuster, and optional other excipients.
[0085] The solid dispersion comprises, by weight, 0.5% to 20% of the pharmaceutical composition (e.g., 0.8% to 15%, 1% to 11%, 1% to 10%, 1% to 9%, 4% to 9%, 5% to 9%, 5.5% to 9%, about 8.5%).
[0086] The filler comprises 25% to 70% by weight of the pharmaceutical composition (e.g., 31% to 50%, 31% to 45%, 31.5% to 43%, 32% to 42%, 32% to 41.5%, 32% to 40%, 32% to 39%, about 33.5%).
[0087] The lubricant is 1% to 3% by weight of the pharmaceutical composition (e.g., 1% to 2.5%, 1.2% to 2%, 1.4% to 2%, about 2%).
[0088] The disintegrant is present in an amount of 10% to 30% by weight of the pharmaceutical composition (e.g., 13% to 25%, 15% to 24%, 16% to 23%, 17% to 22%, 18% to 21%, about 20%); and / or
[0089] The pH adjuster is present in an amount of 0% to 50% by weight of the pharmaceutical composition (e.g., 30% to 45%, 30% to 40%, 32% to 39%, 33% to 38%, 33% to 37%, 34% to 36%, about 35.5%); and / or
[0090] Other excipients, by weight, constitute 0% to 15% of the pharmaceutical composition (e.g., 0% to 10%, 0% to 5%).
[0091] The sum of the weight percentages of the above components is 100%.
[0092] In some embodiments, the pharmaceutical composition comprises, by weight, about 33.8% of the active ingredient in the solid dispersion as described in the first aspect; the carrier is copovidone VA64, which comprises about 66.2% of the solid dispersion by weight; and the composition of each component in the pharmaceutical composition is as described in Examples 4, 10, 11-1, or 11-2 (e.g., Table 11-1). Preferably, the active ingredient is expressed by weight of the hemicalcium salt of the compound represented by formula (I).
[0093] In some embodiments, the pharmaceutical composition is in the form of a solid dosage form or a liquid dosage form (e.g., an injection, a subcutaneous injection); preferably, the solid dosage form is an oral solid dosage form; more preferably, the oral solid dosage form is selected from capsules (e.g., gastric-coated capsules or enteric-coated capsules, preferably gastric-coated capsules) or tablets (e.g., coated tablets, film-coated tablets).
[0094] In some embodiments, each formulation unit of the pharmaceutical composition, solid dosage form, or liquid dosage form contains 0.1 mg to 50 mg (e.g., 0.2 mg to 40 mg, 0.25 mg to 30 mg, 0.25 mg to 25 mg, 0.25 mg to 24 mg, 0.25 mg to 20 mg, 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 12 mg, 15 mg, 16 mg, 18 mg, 20 mg) of an active ingredient; wherein the active ingredient is a compound represented by formula (I) above or a pharmaceutically acceptable salt thereof; preferably, the active ingredient is a hemicalcium salt of a compound represented by formula (I), a compound represented by formula (II), or a compound represented by formula (II'); more preferably, the active ingredient is present in an amorphous form; even more preferably, the content of the active ingredient is based on the compound represented by formula (I) (i.e., in free acid form).
[0095] In some embodiments, the pharmaceutical composition is a capsule or tablet, wherein the capsule or tablet core contains, by weight, 33.8% of the active ingredient in the solid dispersion as described in the first aspect; the carrier is copovidone VA64, which by weight comprises 66.2% of the solid dispersion; and the composition of each component in the pharmaceutical composition is as described in Examples 4, 10, 11-1, or 11-2 (e.g., Table 11-1). Preferably, the active ingredient is expressed by weight of the hemicalcium salt of the compound represented by formula (I).
[0096] In some embodiments, the pharmaceutical composition is a capsule containing, by weight, about 33.8% of the active ingredient in the solid dispersion as described in the first aspect (preferably, the active ingredient is by weight of the hemicalcium salt of the compound shown in formula (I); the carrier is copovidone VA64, which by weight accounts for about 66.2% of the solid dispersion; and the composition of each component in the capsule is shown in the table below:
[0097] or,
[0098] Preferably, the capsule is selected from the group consisting of 0.25 mg, 2 mg and 8 mg; more preferably, the capsule is selected from the group consisting of 2 mg or 8 mg; wherein the specification is based on the weight of the compound represented by formula (I).
[0099] In some embodiments, the pharmaceutical composition is a capsule comprising an active ingredient, by weight, of a solid dispersion as described in the first aspect of this disclosure, comprising about 33.8% of the solid dispersion (preferably, the active ingredient is by weight of the hemicalcium salt of the compound represented by formula (I)); a carrier is copovidone VA64, comprising about 66.2% of the solid dispersion by weight; and the composition of each component in the capsule is shown in the table below:
[0100] or,
[0101] Preferably, the capsule is selected from the group consisting of 0.25 mg, 2 mg and 8 mg; more preferably, the capsule is 8 mg; wherein the specification is based on the weight of the compound represented by formula (I).
[0102] In some embodiments, the pharmaceutical composition is a capsule comprising an active ingredient, by weight, of a solid dispersion as described in the first aspect of this disclosure, comprising about 33.8% of the solid dispersion (preferably, the active ingredient is by weight of the hemicalcium salt of the compound represented by formula (I)); a carrier is copovidone VA64, comprising about 66.2% of the solid dispersion by weight; and the composition of each component in the capsule is shown in the table below:
[0103] or,
[0104] Preferably, the capsule is selected from the group consisting of 0.25 mg, 2 mg and 8 mg; more preferably, the capsule is 0.25 mg; wherein the specification is based on the weight of the compound represented by formula (I).
[0105] The pharmaceutical compositions of the present invention may also contain other excipients besides fillers, lubricants, flow aids, disintegrants, and pH adjusters. Specific examples include binders, flavoring agents, thickeners, dispersants, colorants, fragrances, and coating materials. In embodiments of the present invention, the other excipients constitute 0% to 15% by weight in the pharmaceutical composition (e.g., 0% to 10%, 0% to 5%).
[0106] Fifthly, this disclosure provides the use of the pharmaceutical composition as described in the fourth aspect for activating GLP-1 receptors.
[0107] In some embodiments, this disclosure provides the use of the pharmaceutical composition as described in the fourth aspect for preparing a medicament; preferably, the medicament is a medicament as a GLP-1 receptor agonist; more preferably, the medicament is a medicament for treating diseases mediated by the GLP-1R receptor; more preferably, the medicament is a medicament for treating diabetes, overweight or obesity, liver disease (e.g., non-alcoholic fatty liver disease or fatty liver disease associated with metabolic dysfunction, non-alcoholic steatohepatitis or fatty liver disease associated with metabolic dysfunction), or Alzheimer's disease; even more preferably, the medicament is a medicament for treating type 2 diabetes.
[0108] In some embodiments, this disclosure provides pharmaceutical compositions as described in the fourth aspect for use as GLP-1 receptor agonists; preferably, this disclosure provides pharmaceutical compositions as described in the fourth aspect for treating diseases mediated by GLP-1 receptors; more preferably, this disclosure provides pharmaceutical compositions as described in the fourth aspect for treating diabetes, overweight or obesity, liver disease (e.g., non-alcoholic fatty liver disease or fatty liver disease associated with metabolic dysfunction, non-alcoholic steatohepatitis or fatty liver disease associated with metabolic dysfunction), or Alzheimer's disease; even more preferably, this disclosure provides pharmaceutical compositions as described in the fourth aspect for treating type 2 diabetes.
[0109] In some embodiments, this disclosure provides a method for treating a disease by activating GLP-1 receptors, comprising administering a pharmaceutical composition as described in the fourth aspect; preferably, the method comprises administering a therapeutically effective amount of the pharmaceutical composition as described in the fourth aspect to a subject in need; more preferably, the disease treated by the method of this disclosure is a GLP-1 receptor-mediated disease; more preferably, the disease treated by the method of this disclosure is selected from the group consisting of diabetes, overweight or obesity, liver disease (e.g., non-alcoholic fatty liver disease or metabolically dysfunction-related fatty liver disease, non-alcoholic steatohepatitis or metabolically dysfunction-related steatohepatitis), and Alzheimer's disease; even more preferably, the diabetes is type 2 diabetes.
[0110] In a sixth aspect, this disclosure provides a kit or pharmaceutical kit comprising the pharmaceutical composition as described in the fourth aspect.
[0111] In some embodiments, the kit or cassette described in this disclosure comprises the pharmaceutical composition as described in the fourth aspect and instructions for use (or "instructions for use").
[0112] In a seventh aspect, this disclosure provides a method for preparing the pharmaceutical composition as described in the fourth aspect, comprising: (1) weighing; and (2) mixing.
[0113] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a filler, a lubricant, a disintegrant, and optionally a pH adjuster as described in the first aspect; the preparation method of the pharmaceutical composition comprises: (1) weighing; (2) premixing: adding the solid dispersion and an internal excipient (e.g., a filler, optionally a pH adjuster, an internal disintegrant, an internal lubricant) to a mixing container and mixing to produce a premix; (3) granulation; (4) total mixing: mixing the granules obtained in step (3) with an external excipient (e.g., an external disintegrant, an external lubricant); preferably, further comprising step (5), filling capsules or compressing tablets.
[0114] In some embodiments, the pharmaceutical composition comprises a solid dispersion as described in the first aspect, a filler, a lubricant, a disintegrant, an optional pH adjuster, and optional other excipients, and the preparation method of the pharmaceutical composition comprises: (1) weighing; (2) premixing: adding the solid dispersion and the added excipients (e.g., filler, optional pH adjuster, added disintegrant, added lubricant, optional other added excipients, etc.) to a mixing container to produce a premix; (3) granulation; (4) total mixing: total mixing the granules prepared in step (3) with the added excipients (e.g., added disintegrant, added lubricant, optional other added excipients, etc.); preferably, further comprising step (5), filling capsules or compressing tablets.
[0115] In some embodiments, the pharmaceutical composition comprises a solid dispersion, a filler, a lubricant, a disintegrant, an optional pH adjuster, and optional other excipients as described in the first aspect, and the preparation method of the pharmaceutical composition comprises: (1) weighing; (2) premixing: adding the solid dispersion and the added excipients (e.g., filler, optional pH adjuster, added disintegrant, optional other added excipients, etc.) to a mixing container to produce a premix; (3) granulation: adding the premix obtained in step (2) and the added lubricant to a granulator for granulation and premixing again; (4) granulation; (5) total mixing: total mixing the granules prepared in step (4) with the added excipients (e.g., added disintegrant, added lubricant, optional other added excipients, etc.); preferably, further comprising step (5), filling capsules or compressing tablets.
[0116] In some embodiments, the pharmaceutical composition comprises a solid dispersion as described in the first aspect, a filler, a flow aid, and an optional pH adjuster, and the preparation method of the pharmaceutical composition comprises: (1) weighing; (2) first premixing (premix 1): adding the optional pH adjuster and flow aid to a mixing container and mixing to obtain powder 1; (3) second premixing (premix 2): adding the filler and solid dispersion to a mixing container and mixing to obtain powder 2; (4) final mixing: adding powder 1 and powder 2 to a mixing container and performing final mixing; preferably, further comprising step (4), filling capsules or compressing tablets.
[0117] In some embodiments, the pharmaceutical composition comprises a solid dispersion as described in the first aspect, a filler, a flow aid, an optional pH adjuster, and optional other excipients, and the method for preparing the pharmaceutical composition comprises: (1) weighing; (2) first premixing (premix 1): adding the optional pH adjuster, flow aid, and optional other excipients to a mixing container and mixing to obtain powder 1; (3) second premixing (premix 2): adding the filler, solid dispersion, and optional other excipients to a mixing container and mixing to obtain powder 2; (4) final mixing: adding powder 1 and powder 2 to a mixing container and final mixing; preferably, further comprising step (4) filling capsules or compressing tablets.
[0118] In some embodiments, the granulation is dry granulation or wet granulation; preferably, it is dry granulation.
[0119] In some embodiments, the added excipients include pH adjusters, fillers, added lubricants, and added disintegrants.
[0120] In some embodiments, the added excipients include added lubricants and added disintegrants. Attached image description:
[0121] Figure 1 is a powder X-ray diffraction pattern of the product (i.e., crystal form I) of Example 1 of this disclosure.
[0122] Figure 2 is a TGA thermal analysis diagram of the product of Embodiment 1 of this disclosure.
[0123]
definition
[0124] The terms used in this disclosure have their common meanings in the art, unless otherwise specified herein. Unless otherwise stated, the following terms and phrases as used herein are intended to have the following meanings. A particular phrase or term should not be considered uncertain or unclear unless specifically defined, but should be understood in its ordinary sense. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.
[0125] Unless otherwise specified, all percentages are given as weight percent of the total weight of the pharmaceutical composition or its oral formulation.
[0126] The "oral preparation" or "oral dosage form" mentioned in this disclosure refers to a pharmaceutical preparation intended for oral administration.
[0127] The term "oral solid dosage form" as used in this disclosure refers to a solid pharmaceutical preparation intended for oral administration.
[0128] In embodiments of this disclosure, the drug can be administered to humans or non-human mammals, more preferably humans.
[0129] In embodiments of this disclosure, the terms “comprising,” “including,” and “containing” generally have an open meaning, but within their scope also include closed meanings defined as “composed of.” For example, “the pharmaceutical composition comprises the solid dispersion, filler, flow aid, and pH adjuster as described in the first aspect” also includes “the pharmaceutical composition is composed of the solid dispersion, filler, flow aid, and pH adjuster as described in the first aspect.”
[0130] Within the scope of this disclosure, various options for any feature can be combined with various options for other features to form a number of different embodiments. This disclosure is intended to include all possible embodiments comprised of various options for all technical features.
[0131] Within the scope of this disclosure, when expressed as "a to b" or "a ~ b", it means point values that include a and b, and consecutive values falling within its range.
[0132] The terms "optional," "optional," or "optionally" used in this disclosure mean that the events, circumstances, or situations subsequently described may but do not occur, including situations where such events, circumstances, or situations may or may not occur. For example, "optionally, further comprising a disintegrant" means that a disintegrant may but does not have to be present, and this description includes situations where the pharmaceutical composition contains a disintegrant and situations where it does not contain a disintegrant.
[0133] Within the scope of this disclosure, the amount of an active ingredient (e.g., a hemicalcium salt of a compound represented by formula (I), a compound represented by formula (II), or a compound represented by formula (II')) or a solid dispersion in the composition may be appropriately adjusted, or the ratio (mass ratio) with the excipient may be adjusted, to obtain pharmaceutical compositions or oral formulations containing different strengths or different drug weights, which also fall within the scope of this disclosure.
[0134] The term "hydrate" refers to an associative compound formed by stoichiometric or non-stoichiometric water molecules with a hemicalcium salt of the compound represented by formula (I), the compound represented by formula (II), or the compound represented by formula (II') of this disclosure.
[0135] Unless otherwise specified, the terms "pharmaceutically acceptable salt" or "medicinal salt" refer to a salt that, to the extent of reasonable medical judgment, is suitable for contact with the tissues of mammals, particularly humans, without excessive toxicity, irritation, allergic reactions, etc., and in a manner commensurate with a reasonable benefit / risk ratio. Medically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. The salts may be prepared in situ during the final isolation and purification of the compounds disclosed herein, or solely by reacting a free base or free acid with a suitable reagent.
[0136] The compounds disclosed herein also include their isotopic derivatives. Unless otherwise specified, the term "isotopic derivative" refers to compounds of this disclosure that can exist in an isotopically traced or enriched form, containing one or more atoms whose atomic weights or mass numbers differ from the atomic weights or mass numbers of the most abundant atoms found in nature. Isotopes can be radioactive or non-radioactive isotopes. Commonly used isotopes for isotopic labeling include hydrogen isotopes. 2 H and 3 H; Carbon isotopes: 13 C and 14 C; Chlorine isotopes: 35 Cl and 37 Cl; Fluorine isotopes: 18 F; Iodine isotopes: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; oxygen isotopes: 15 O, 17 O and 18 O and sulfur isotopes 35 S. These isotope-labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues. Especially 3 H and 13 C, because they are easy to label and convenient to detect, are more widely used. Some heavy isotopes, such as deuterium (… 2 Substitution with H can enhance metabolic stability and prolong the half-life, thereby achieving the goal of reducing dosage and providing therapeutic advantages. Isotope-labeled compounds are generally synthesized from labeled starting materials using known synthetic techniques, just like non-isotope-labeled compounds. The isotope derivatives are preferably deuterated derivatives.
[0137] In this document, "about" or "approximately" means ±5%; preferably ±3%; more preferably ±2%; and even more preferably ±1%.
[0138] The term "substantially as shown in the attached figure" means that at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% of the peaks in the given spectrum are present in a substantially pure crystal form, either in its powder X-ray diffraction pattern, its DSC pattern, or in the crystal shape diagram of the crystalline particles. Furthermore, as the content of a certain crystal form in a product gradually decreases, some diffraction peaks attributable to that crystal form in its powder X-ray diffraction pattern may decrease due to factors such as the instrument's detection sensitivity. In addition, for any given crystal form, the peak positions may have slight errors, which is well known in the field of crystallography. For example, due to temperature changes during sample analysis, sample movement, or instrument calibration, the peak positions can shift, and the determination error of the 2θ value is typically about ±0.2°. Therefore, this error should be taken into account when determining each crystal structure, and the terms "substantially" or "substantially as shown in the figure" are also intended to cover such differences in diffraction peak positions.
[0139] The term "excipient" as used in this disclosure, also known as "pharmaceuticalally acceptable excipient," "excipient," or "additional agent," refers to all additional materials used in the formulation and production of pharmaceuticals, excluding the active ingredient. These are generally pharmaceutically acceptable inert ingredients that have undergone reasonable safety assessments. Examples of excipients, without limitation, include solid dispersion carriers, fillers (or diluents), disintegrants, lubricants, flow aids, anti-adhesion agents, binders, stabilizers, flavoring agents, thickeners, dispersants, colorants, antibacterial agents, antioxidants, pH adjusters, surfactants, fragrances, and coating materials (including plasticizers, opacifiers, pigments, etc.). For example, excipients can enhance the operational characteristics of pharmaceutical formulations, such as by increasing flowability and / or adhesion to ensure the formulation meets process requirements. Furthermore, the "excipient" should possess good compatibility with the active ingredient, meaning that the excipient itself or its impurities will not chemically react with the structural groups in the active ingredient or cause degradation of the active ingredient, resulting in a decrease in the content of the active ingredient.
[0140] The term "filler" or "diluent" as used in this disclosure refers to an excipient used to increase the weight and volume of a pharmaceutical composition to facilitate shaping and dispensing. The filler described in this disclosure may be a single filler or a mixture of two or more fillers.
[0141] The term "disintegrant" as used in this disclosure refers to an excipient used to promote the disintegration of a pharmaceutical composition in the gastrointestinal tract and increase the dissolution rate of the active ingredient.
[0142] The "lubricant" mentioned in this disclosure refers to a lubricating excipient used in the preparation of solid dosage forms, which reduces the friction between particles and between the metal contact surfaces of particles and solid dosage form production equipment (such as tablet press punches and dies).
[0143] The "flow aid" described in this disclosure refers to an excipient that can reduce the friction between particles and thus improve the flowability of powders (granules). Its main function is to increase the flowability of granules, increase the powder flow rate, and improve the uniformity of the formulation.
[0144] The “pH adjuster” mentioned in this disclosure refers to a class of pharmaceutical excipients used in the pharmaceutical manufacturing process to control pH or adjust the acidity or alkalinity of pharmaceuticals. Detailed Implementation
[0145] The technical solutions of this disclosure will be further described in detail below with reference to specific embodiments or test examples. The following embodiments or test examples are merely illustrative and explanatory of this disclosure and should not be construed as limiting the scope of protection of this disclosure. Non-essential improvements and adjustments made to the implementation schemes by those skilled in the art based on the above-described invention content still fall within the scope of protection of this disclosure. Unless otherwise stated, the raw materials and reagents (e.g., organic solvents, inorganic solvents, buffer solutions, excipients, etc.) used in the following embodiments and test examples are all commercially available products, or can be prepared or formulated by known methods or reagent instructions. For process parameters not specifically specified, conventional techniques can be referred to. In the following embodiments, the analytical detection conditions are as follows:
[0146] 1. X-ray Powder Diffraction (XRPD)
[0147] (1) Instrument model: Bruker D8 Advance Diffractometer
[0148] Target: Cu Kα (40 kV, 40 mA), Wavelength:
[0149] Step angle: 0.02°
[0150] Scanning speed: 0.02° / 0.2s.
[0151] (2) Testing instrument: Bruker D2 PHASER powder X-ray diffractometer
[0152] Test conditions (accelerated stability test):
[0153] CuKa radiation, graphite monochromator, 30kV, 10mA, scan rate 0.2s, step size: 0.02°.
[0154] 2. Thermogravimetric analyzer (TGA)
[0155] Instrument Model: TA Instruments Q200 TGA
[0156] Test method: The sample was heated from 5℃ to 450℃ at a heating rate of 10℃ / min, and the nitrogen flow rate was 50mL / min.
[0157] 3. Solubility
[0158] Preparation of FaSSGF solution, FaSSIF-V2 solution, FeSSIF-V2 solution, hydrochloric acid buffer (pH 1.2), phosphate buffer (pH 6.8), and phosphate buffer (pH 7.4): Prepare according to existing conventional methods.
[0159] Detection was performed according to the high-performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512). Exemplary chromatographic conditions:
[0160] 4. Content or related substance testing
[0161] Detection instrument: Agilent 1260 (LC1260-3-DAD) high performance liquid chromatograph
[0162] The content was determined according to the high performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512):
[0163] The relevant substances were detected according to the high performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512):
[0164] 5. Dissolution test
[0165] The method of dissolution and release determination (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0931, Method II) and high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapter 0512) were used for detection.
[0166] Exemplary dissolution determination method and experimental conditions:
[0167] Exemplary liquid chromatography conditions for dissolution determination:
[0168] 6. Determination of particle size distribution of solid dispersions
[0169] 7. Ion Chromatograph (IC)
[0170] Abbreviations and their corresponding names:
[0171] DCM: Dichloromethane; MTBE: Methyl tert-butyl ether; DMF: N,N-dimethylformamide; HATU: 2-(7-azobenzotriazole)-N,N,N′,N′-tetramethylurea hexafluorophosphate; DIEA: N,N-diisopropylethylamine; EA: Ethyl acetate.
[0172] Example 1: Preparation of the hemicalcium salt of the compound shown in formula (I)
[0173] 1) Preparation of the compound shown in formula (I):
[0174] Step 1: Preparation of intermediate I-1
[0175] Add SM1 (15.0 g, 1.0 eq.), SM2 (13.1 g, 1.5 eq.), CuI (3.24 g, 0.5 eq.), (1S,2S)-(+)-N,N-dimethylcyclohexanediamine (9.6 g, 2.0 eq.), potassium phosphate (21.6 g, 3.0 eq.), anhydrous dioxane (75 mL), and methyltetrahydrofuran (75 mL) to the reaction flask, and heat to 90 °C with stirring for 5 hours. After the reaction is complete, filter and concentrate to dryness; wash the organic phase with water and 0.1 M hydrochloric acid, respectively, and dry the organic phase with anhydrous magnesium sulfate; filter, concentrate to dryness under reduced pressure, and use directly in the next step.
[0176] Step 2: Preparation of intermediate I-2
[0177] Intermediate I-1 (12 g) obtained in step 1 was dissolved in dioxane (16.5 mL), and a dioxane solution of hydrogen chloride (4 M, 16.5 mL) was added until completely dissolved. The mixture was stirred at room temperature for 2 hours. After the reaction was completed, the crude product was directly concentrated. H2O (100 mL) was added, and the pH was adjusted to 3-5 with hydrochloric acid. The mixture was extracted three times with MTBE. The aqueous phase was then extracted with 10% NaOH aqueous solution to adjust the pH to 10-12. The mixture was extracted with DCM, and the organic phase was collected, concentrated, and finally MTBE was added. The mixture was cooled to 0-5 °C and stirred to induce crystallization. The crystals were filtered, and the filter cake was dried under vacuum at 65 °C for 5 hours to obtain the product (7.0 g), which was directly used in the next reaction.
[0178] Step 3: Preparation of Compound I
[0179] DMF (70 mL), SM3 (11.7 g, 1.05 eq.), and HATU (15.5 g, 1.5 eq.) were added to the reaction flask, and the temperature was lowered to 10 °C. DIEA (14 g, 4.0 eq.) was added, and the mixture was stirred at 10 °C for 0.5 h. I-2 (14 g, 1.0 eq.) was added, and the temperature was raised to 25 °C and stirred for 6 h. After the reaction was complete, water was added to quench the reaction mixture, and the temperature was lowered to 10 °C. Water (20 v / w, based on 1 eq. of raw material) was added, and EA (5 v / w) was stirred and the temperature was lowered to 10 °C. The mixture was extracted with EA, and the organic phase was collected. The organic phase was concentrated to dryness, and the crude product was purified by column chromatography (dichloromethane:methanol = 80:1) to obtain a pale yellow solid (16.4 g). XRPD analysis showed that it was in an amorphous form, with a yield of 66.7%.
[0180] The compound shown in formula (I) can also be prepared by referring to the method (Example 10) in PCT / CN2024 / 140920, the entire contents of which are incorporated herein by reference.
[0181] 2) Preparation of the hemicalcium salt of the compound shown in formula (I)
[0182] Add 1.5 g of the product obtained in step 1) to a reaction flask, then add 7 mL of ethanol. After 15 min, add 0.97 mL of 2.0 M NaOH aqueous solution, completing the addition within 0.5 h. Raise the temperature to 55 °C, then add 1.38 mL of 1.0 M Ca(AcO)₂ aqueous solution, completing the addition within 0.5 h. Raise the temperature to 60 °C, maintain the temperature and stir for 2 h. Cool down, and when the temperature drops to 30 °C, a small amount of insoluble matter precipitates. Add 7.1 mL of water dropwise, completing the addition within 0.5–1 h. Stir for 12 h, then continue adding 7.1 mL of water dropwise, completing the addition within 0.5–1 h. Stir at room temperature for 4 h, filter, wash the filter cake with water, and dry under vacuum at 65 °C (approximately 20 h) to obtain a white solid. Ion chromatography analysis shows that the free state forms a salt with calcium ions in a ratio of approximately 1:0.5.
[0183] The obtained product sample was subjected to powder X-ray diffraction, which showed that it was a calcium salt crystal form I, as shown in Figure 1. The data results are shown in Table 1. TGA thermal analysis results showed that there was weight loss between 15℃ and 150℃, and a weight loss of 2.968% between 60℃ and 150℃. The solvent was identified as water, and the decomposition temperature was approximately 329℃, as shown in Figure 2.
[0184] Table 1. Powder-X-ray diffraction peak data of the product from Example 1
[0185] It can also be prepared by referring to the method of Example 8 in PCT / CN2026 / 094091.
[0186] Unless otherwise specified below, the product of Example 1 refers to the hemicalcium salt of the compound shown in formula (I).
[0187] Example 2: Preparation of Solid Dispersion (SDD)
[0188] Table 2-1 Composition of the solid dispersion in Example 2
[0189] Table 2-2 Solvents required for preparing the solid dispersion in Example 2 Note: At this solvent dosage, the total content of active ingredient and solid dispersion carrier after preparation into a solution is 20% (mass fraction).
[0190] Preparation method:
[0191] (1) Solution preparation: Weigh anhydrous ethanol and methanol separately and mix them evenly; slowly add copovidone VA64 to the mixed solution and stir until completely dissolved; then add the product of Example 1 to the above solution and stir to dissolve.
[0192] (2) Preparation of solid dispersion: The prepared solution is spray-dried on a conventional spray dryer with a pressure nozzle. For example, the relevant parameters can be seen in Table 2-3 below.
[0193] Table 2-3 Process parameters for preparing solid dispersions
[0194] Table 2-4 Results of Particle Size and Content Tests for Solid Dispersions
[0195] Example 3: Screening of solvent ratios for preparing solid dispersions
[0196] The product of Example 1 and the solid dispersion carrier were selected to be soluble in solvents with good solubility, namely methanol and / or ethanol, for screening tests of solvent ratio.
[0197] Table 3. Screening criteria and results
[0198] Results: As shown in the table above, when the ethanol to methanol ratio was 0:1, 6:1, or 19:1, both the copovidone and the active ingredient dissolved rapidly, and the solution remained clear after 24 hours, all meeting the requirements. A 19:1 ethanol to methanol mixture was selected as the processing solvent for the solid dispersion and for subsequent formulation preparation.
[0199] Example 4: Preparation of capsules containing the solid dispersion described in this disclosure
[0200] Table 4-1 Capsule Composition (40,000 capsules) Note: The specification is 8mg, calculated based on the compound shown in formula (I).
[0201] Preparation method: (1) First premix (premix 1): Add the internal additives (except for internal magnesium stearate) listed in the table above to a mixer (e.g., WHJ-100 mobile micro mixer) for premixing. The mixing speed is 10 rpm and the mixing time is 600 s. (2) Granulation: Add the material obtained from premix 1 and internal magnesium stearate to a granulator (e.g., YZLJ-125) for granulation. The screen aperture is 1 mm. (3) Second premix (premix 2): Add the granulated material to a mixer (e.g., YHA-2C fully automatic lifting mixer) for mixing. The mixing speed is 10 rpm and the mixing time is 900 s. (4) Dry granulation: Add the mixed powder obtained in step (3) to a granulator (e.g., model CCS320), with a horizontal feed speed of 10.0-19.0 rpm, a vertical feed speed of 190-210 rpm, a roller speed of 4.5-5.5 rpm, a roller pressure of 2.0-4.5 KN / cm, and a screen aperture of 0.8 mm. The dry granulated particles are then screened using a high-energy sieve (screen aperture: 40 mesh, 100 mesh), and particles larger than 40 mesh are discarded. (5) Blending: Add the added crosslinked polyvinylpyrrolidone XL and added magnesium stearate to the screened particles and blend them in a mixer (e.g., YHA-2C fully automatic lifting mixer). (6) Capsule filling.
[0202] Table 4-2 Test results of active ingredient content in granules 1
[0203] Content test results showed that the average content of active ingredients was qualified after premixing and total mixing.
[0204] Table 4-2' Test results of active ingredient content in granules 2
[0205] Content test results showed that the average content of active ingredients was qualified after premixing and total mixing.
[0206] Table 4-3 Dissolution Test Results 1
[0207] Dissolution test results show that rapid dissolution can be achieved.
[0208] Table 4-3 Dissolution Test Results 2
[0209] Dissolution test results show that rapid dissolution can be achieved.
[0210] Example 5: Screening of the amount of mixed solvent used in the preparation of solid dispersions
[0211] Referring to the composition and preparation method of Example 2, the ratio of anhydrous ethanol to methanol was kept at 19:1. The total amount of mixed solvent was adjusted, that is, the content ratio of solid dispersion (solid content) was adjusted, in order to screen the amount of solvent used in the preparation process of solid dispersion.
[0212] Table 5-1 Solid dispersions obtained after adjusting the total amount of processing solvent
[0213] Following the composition and preparation method of Example 4, capsules were prepared using the solid dispersions obtained in Examples 5-1 and 5-2 as materials, resulting in capsules of Examples 5-3 and 5-4, respectively.
[0214] Table 5-2 Capsules (granules) prepared using the solid dispersions obtained in Examples 5-1 and 5-2
[0215] Table 5-3 Results of Solid Dispersion Content Test
[0216] Table 5-4 Test results of active ingredient content in the mixed granules
[0217] Content test results showed that the average content of active ingredients was qualified after premixing and total mixing.
[0218] Table 5-5 Dissolution test results of capsules with different compositions
[0219] Dissolution test results show that rapid dissolution can be achieved.
[0220] Example 6: Investigation of the Amount of Solid Dispersion Carrier
[0221] Referring to the composition and preparation method of Example 2, different solid dispersions were prepared by adjusting the amount of copovidone, namely Examples 6-1 and 6-2. Referring to the composition ratio and preparation method of Example 4, capsules of Examples 6-3 and 6-4 were prepared respectively.
[0222] Table 6-1 Composition of capsules obtained by adjusting the amount of copovidone
[0223] Table 6-2 Results of Solid Dispersion Content Test
[0224] Table 6-3 Dissolution Test Results
[0225] Example 7: Investigation of Particle Size of Solid Dispersion
[0226] Referring to the solid dispersion composition and preparation method of Example 2, solid dispersions of different particle sizes were obtained by controlling the preparation process of the solid dispersion (e.g., adjusting the atomizing gas flow rate (reducing the atomizing gas flow rate to obtain a solid dispersion with larger particle size), and / or adjusting the liquid inlet flow rate (reducing the liquid inlet flow rate to obtain a solid dispersion with smaller particle size)). Referring to the formulation composition and preparation method of Example 4, capsules of Examples 7-1 and 7-2 were prepared respectively, and dissolution tests were performed to investigate the effect of solid dispersion particle size on dissolution.
[0227] Table 7. Results of particle size test for solid dispersions and corresponding dissolution test results.
[0228] Dissolution test results show that rapid dissolution can be achieved.
[0229] Example 8: Screening of pH Adjuster Dosage
[0230] Using the solid dispersion prepared in Example 2, and referring to the composition and preparation method in Example 4, the amount of pH adjuster was adjusted, and the dissolution results of the resulting formulation were examined.
[0231] Table 8-1 Formulation obtained by adjusting the dosage of pH adjuster Note: The reduction in the amount of pH adjuster was compensated for by adjusting the filler to bring the total amount back to 100%.
[0232] Table 8-2 Dissolution Test Results 1
[0233] Table 8-3 Dissolution Test Results 2
[0234] Example 9: Screening of disintegrant dosage
[0235] Using the solid dispersion prepared in Example 2, and referring to the composition and preparation method of Example 4, the amount of disintegrant was adjusted, and the dissolution results of the obtained formulations were examined to prepare the formulations of Examples 9-1 and 9-2, respectively.
[0236] Table 9. Formulations obtained after adjusting the amount of disintegrant. Note: Changes in the amount of disintegrant were compensated for by adjusting the filler to ensure that the total amount was 100%.
[0237] Example 10: Adjustment of Lubricant Dosage
[0238] Using the solid dispersion prepared in Example 2, and referring to the composition and preparation method in Example 4, the amount of lubricant was adjusted, and the dissolution results of the resulting formulation were examined.
[0239] Table 10 shows the formulation obtained after adjusting the amount of lubricant. Note: The reduction in lubricant usage was compensated for by adjusting the filler to ensure the total amount was 100%.
[0240] Dissolution test results show that rapid dissolution can be achieved.
[0241] Example 11: Capsules of different sizes
[0242] Using the solid dispersion of Example 2, and referring to the formulation composition and preparation method of Example 4, capsules of different specifications were prepared.
[0243] Table 11-1 Capsules of different specifications Note: Specifications of 0.25mg, 2mg and 8mg are all based on the weight of the compound shown in formula (I).
[0244] Table 11-2 Dissolution test results in pH 6.8 phosphate buffer (containing 0.3% SDS)
[0245] Table 11-3 Dissolution test results in pH 4.5 acetate buffer (containing 0.3% SDS)
[0246] Example 12: Composition of solid dispersion
[0247] Solid dispersions of different specifications were prepared by referring to the preparation method of solid dispersion in Example 2.
[0248] Table 12-1 Composition of solid dispersions of different specifications
[0249] Preparation method: (1) First premix (premix 1): Add NaHCO3 and colloidal silica to a self-sealing bag and mix manually 10 times, then pass through a 40-mesh sieve 3 times; (2) Second premix (premix 2): Add microcrystalline cellulose 102 and SDD to a self-sealing bag and mix manually 100 times, then pass through a 40-mesh sieve 3 times; (3) Third premix (premix 3): Add premix 1 to premix 2 and mix manually 100 times, then pass through a 40-mesh sieve 3 times; (4) Fill capsules.
[0250] Table 12-2 Dissolution Test Results
[0251] Example 13: Formulation of solid dispersions
[0252] Referring to the preparation method of the solid dispersion in Example 12, and with the mass ratio of the sample of Example 1 to copovidone VA64 being 1 / 3 (in the form of free acid (i.e., the compound shown in formula (I))), a formulation having the following composition was prepared.
[0253] Table 13-1 Formulation of solid dispersions (made into 30 capsules)
[0254] Table 13-2 Dissolution Test Results
[0255] Example 14: Preparation of the amorphous form of the hemicalcium salt of the compound shown in formula (I)
[0256] Approximately 50 mg of the product obtained in Example 1(1) was added to 0.3 mL of acetonitrile and 0.031 mL of sodium hydroxide aqueous solution (2M). The solution was stirred at room temperature to dissolve the product, resulting in a clear solution. 0.033 mL of calcium acetate aqueous solution (1.26M) was added dropwise to the clear solution, followed by the slow addition of 0.9 mL of water to precipitate a solid. After the addition was complete, the mixture was stirred at room temperature for 3 days. The precipitated solid was then separated by centrifugation and filtration. The obtained solid was vacuum dried overnight at 40°C, yielding the amorphous form of the hemicalcium salt of the compound shown in formula (I). Ion chromatography analysis showed that the free state formed a salt with calcium ions at a ratio of approximately 1:0.47.
[0257] Test Example 1: Long-term stability determination of the product of Example 1
[0258] Test Example 2: Solubility Test of the Product of Example 1
[0259] Solubility tests were conducted, and the following are some examples of the results:
[0260] Test Example 3: Influencing Factors Experiment and Results
[0261] The stability of the formulations in the various embodiments of this disclosure was tested under different influencing factor conditions. The stability results of exemplary formulations are as follows:
[0262] Table 13 Results of the test on the influencing factors of the formulation in Example 4 Note: The dissolution test conditions are the same as in Example 4, and the same applies below.
[0263] Results: The formulations of the above examples showed good stability under different conditions.
[0264] Test Example 4: Accelerated Stability Test
[0265] The stability of the formulations in the various embodiments of this disclosure was tested under conditions of 40°C ± 2°C and 75% ± 5% relative humidity. The stability results of exemplary formulations are as follows:
[0266] Table 14-1 Stability results of the formulation in Example 4 under accelerated conditions
[0267] Table 14-2 Stability results of the formulation of Example 11-1 under accelerated conditions
[0268] Table 14-3 Stability results of the formulations in Examples 11-2 under accelerated conditions.
[0269] Results: The formulations of the above examples showed good stability under accelerated conditions.
[0270] Test Example 5: Pharmacokinetic (PK) Study in Cynomolgus Monkeys
[0271] 1. Experimental objective: To study the pharmacokinetics of the capsule disclosed herein in cynomolgus monkeys.
[0272] 2. Laboratory animals: Crab-eating macaques (e.g., Suzhou Haike Pharmaceutical Technology Co., Ltd.), weighing 3-7 kg, number 2-4.
[0273] 3. Test methods:
[0274] (1) The cynomolgus monkeys were fasted for 12 hours before administration and fed uniformly 4 hours after administration.
[0275] (2) Before administration (0h), and at 0.25, 0.5, 10, 2.0, 40, 8.0, 12, 24, or 48 hours after administration, whole blood (0.5 mL) was collected via the forelimb vein and placed in an EP tube containing EDTA-K. The tube was gently shaken to mix, and immediately placed in an ice-water bath. The plasma was centrifuged at 2000g for 10 minutes at 4°C within 30 minutes to separate the plasma. The plasma was then immediately frozen at -70°C for analysis. (Ice-water bath procedure.)
[0276] Note: An additional 4 ml of blank plasma from cynomolgus monkeys was collected for the preparation of the standard curve.
[0277] The test results of the exemplary capsule embodiments are shown in Table 15 below.
[0278] Table 15-1 Pharmacokinetic Study of the Capsules in Example 4 in Cynomolgus Monkeys
[0279] The equivalent dose is 2.67 mg / kg.
[0280] Table 15-2 Pharmacokinetic Study of the Product of Example 1 in Cynomolgus Monkeys
[0281] Strong solvent system: 2.5% DMSO + 10% EL35 + 15% PEG400 + 72.5% (100mM glycine-NaOH buffer, pH=10), all clear solutions.
[0282] Test Example 6: Pharmacokinetic Study in SD Rats
[0283] 1. Experimental objective: To investigate the pharmacokinetics of the amorphous / crystalline form of the hemicalcium salt of the compound shown in formula (I) in SD rats after a single oral administration.
[0284] 2. Laboratory animals
[0285] SD rats, SPF grade, male, 180-240g, 3 rats / group, Beijing Vital River Co., Ltd.
[0286] 3. Test methods
[0287] (1) Mice were divided into groups of 3 according to the experimental protocol. Animals were fasted for 12 hours before administration, but water was allowed. On the day of the experiment, the drug solution was taken according to the animal's body weight and administered to the mice sequentially according to the experimental protocol. Blood samples were collected from the mice after administration according to the protocol.
[0288] (2) Sample collection: At 0.25h, 0.5h, 1h, 2h, 4h, 8h, 24h and 48h after the administration of the drug, 200μL of blood was collected from the orbital vein of the rats and placed in EDTA anticoagulant tubes. The blood was centrifuged at 8000 rpm for 10min, and the plasma was transferred to 1.5mL centrifuge tubes and stored in a -80℃ refrigerator for testing.
[0289] 4. Test Results
[0290] Table 16: Pharmacokinetic Results in SD Rats Note: Dosage is in free acid form.
[0291] Note: Reference may also be made to Example 15 and Test Example 6 in PCT / CN2026 / 094091, the entire contents of which are incorporated herein by reference.
Claims
1. A solid dispersion comprising an active ingredient and a solid dispersion carrier, the active ingredient being a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, ###000001@ Formula (I) Alternatively, the active ingredient is a hemicalcium salt of the compound shown in formula (I).
2. The solid dispersion of claim 1, wherein, The solid dispersion carrier is selected from polymer carriers; preferably polyethylene glycol or copovidone; more preferably copovidone VA64.
3. The solid dispersion of claim 1 or 2, wherein, The active ingredient constitutes 20% to 55% of the weight of the solid dispersion; or 23% to 54%; or 24% to 52%; or 30% to 35%.
4. The solid dispersion according to any one of claims 1-3, wherein, The solid dispersion carrier accounts for 40% to 80% of the weight of the solid dispersion; or 45% to 70%; or 46% to 69%; or 47% to 68%; or 48% to 67%; or 49% to 66.5%; or 50% to 67%; or about 65%; or about 66%.
5. The solid dispersion of any one of claims 1-4, wherein, The particle size D of the solid dispersion 90 ≤ 150 μm; or D 90 ≤ 100 μm; or D 90 ≤ 90 μm; or D 90 ≤ 80 μm; or D 90 ≤ 70 μm; or D 90 ≤ 60 μm; or D 90 ≤ 55 μm; or D 90 ≤ 50 μm.
6. Use of the solid dispersion as described in any one of claims 1-5 in the preparation of a medicament; or, the medicament is a medicament as a GLP-1 receptor agonist; or, the medicament is a medicament for treating diseases mediated by the GLP-1 receptor; or, the medicament is a medicament for treating diabetes, overweight or obesity, liver disease, or Alzheimer's disease; or, the medicament is a medicament for treating non-alcoholic fatty liver disease or metabolic disorder-associated fatty liver disease (MASLD), non-alcoholic steatohepatitis or metabolic disorder-associated steatohepatitis (MASH); or, the medicament is a medicament for treating type 2 diabetes.
7. A pharmaceutical composition comprising the solid dispersion as described in any one of claims 1-5.
8. The pharmaceutical composition of claim 7, wherein, The pharmaceutical composition further comprises an excipient selected from one or more fillers, lubricants, and flow aids; optionally, the excipient also comprises a disintegrant and / or a pH adjuster. Alternatively, the pharmaceutical composition may further comprise a filler, a flow aid, and a pH adjuster; Alternatively, the pharmaceutical composition may further comprise a pH adjuster, a filler, a lubricant, and a disintegrant.
9. The pharmaceutical composition according to claim 7 or 8, wherein, The solid dispersion, by weight, comprises 0.5% to 45% of the pharmaceutical composition; or 0.8% to 43%; or 1% to 42%; or 1% to 41%; or 1% to 40%; or 0.5% to 20%; or 0.8% to 15%; or 1% to 11%; or 1% to 10%; or 1% to 9%; or 4% to 9%; or 5% to 9%; or 5.5% to 9%; or about 8.5%; or 5% to 41%; or 8% to 40%; or 10% to 30%; or 12% to 25%; or 13% to 22%; 13.3% to 20%, 0.8% to 30%, 0.8% to 25%, 1% to 25%, 1% to 20%, or 1% to 15%.
10. The pharmaceutical composition according to any one of claims 7-9, wherein: The filler is selected from microcrystalline cellulose, microcrystalline cellulose colloidal silica co-treated material, mannitol, lactose cellulose, starch, lactose, or pregelatinized starch; or, the filler is microcrystalline cellulose or microcrystalline cellulose colloidal silica co-treated material; or, the microcrystalline cellulose is microcrystalline cellulose 102, and the microcrystalline cellulose colloidal silica co-treated material is microcrystalline cellulose colloidal silica co-treated material 90; and / or, The lubricant is selected from one or more of starch, polyethylene glycol, magnesium stearate, calcium stearate, sodium benzoate, sodium lauryl sulfate, zinc stearate, sodium stearate fumarate, magnesium stearate fumarate, magnesium lauryl sulfate, sodium lauryl sulfate, or magnesium lauryl sulfate; or, the lubricant is magnesium stearate; and / or The flow aid is colloidal silica; and / or, The disintegrant is selected from one or more of sodium carboxymethyl starch, croscarmellose, and croscarmellose; or, the disintegrant is croscarmellose; or, the disintegrant is croscarmellose XL; and / or, The pH adjuster is selected from one, two, or a combination of more than one of sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium hydroxide, calcium hydroxide, or magnesium oxide; or, the pH adjuster is sodium bicarbonate; or, the pH adjuster is anhydrous sodium bicarbonate or hydrated sodium bicarbonate; or, the pH adjuster is anhydrous sodium bicarbonate.
11. The pharmaceutical composition of claim 10, wherein, The filler, by weight, comprises 10% to 75% of the pharmaceutical composition; or 10.5% to 70%; or 11% to 70%; or 25% to 70%; or 31% to 50%; or 31% to 45%; or 31.5% to 43%; or 32% to 42%; or 32% to 41.5%; or 32% to 40%; or 32% to 39%; or about 33.5%; or 10% to 60%; or 11% to 57%; or 11% to 55%; or 15% to 35%; or 17% to 30%; or 18% to 28%; and / or, The gliding agent, by weight, comprises 0.5% to 7% of the pharmaceutical composition; or 1% to 6%; or 1% to 5.5%; or 1% to 5%; or 1.5% to 3%; or 1.5% to 2.5%; and / or, The lubricant, by weight, comprises 1% to 3% of the pharmaceutical composition; or 1% to 2.5%; or 1.2% to 2%; or 1.4% to 2%; or about 2%; and / or, The disintegrant, by weight, comprises 0% to 35% of the pharmaceutical composition; or 0% to 30%; or 0% to 25%; or 0% to 20%; or 10% to 30%; or 13% to 25%; or 15% to 24%; or 16% to 23%; or 17% to 22%; or 18% to 21%; or about 20%; and / or, The pH adjuster, by weight, comprises 0% to 85% of the pharmaceutical composition; or 0% to 80%; or 30% to 80%; or 0% to 50%; or 30% to 45%; or 30% to 40%; or 32% to 39%; or 33% to 38%; or 33% to 37%; or 34% to 36%; or about 35.5%; Or 0% to 80%; or 40% to 80%; or 45% to 75%; or 48% to 70%; or 50% to 68%.
12. The pharmaceutical composition of claim 10, wherein, The disintegrant is divided into internal disintegrant and external disintegrant, wherein the weight ratio of the internal disintegrant to the external disintegrant is 1:4 to 4:1; or 1:3.5 to 3.5:1; or 1:3 to 3:1; or 1:2 to 2:1; or (1 to 3):1; or 3:1, 2:1 or 1:
1.
13. The pharmaceutical composition according to any one of claims 7-12, wherein, The pharmaceutical composition is a solid dosage form or a liquid dosage form; or... The solid dosage form is an oral solid dosage form; or, the oral solid dosage form is selected from capsules or tablets; or, the capsules are gastric-coated capsules or enteric-coated capsules, and the tablets are coated tablets; or... Each formulation unit of the solid or liquid formulation contains 0.1 mg to 50 mg of an active ingredient by weight; wherein the active ingredient is a compound of formula (I) or a pharmaceutically acceptable salt thereof; or, the active ingredient is a hemicalcium salt of a compound of formula (I); wherein the weight of the active ingredient is based on the compound of formula (I).
14. Use of the pharmaceutical composition according to any one of claims 7-13 in the preparation of a medicament; or, the medicament is a medicament as a GLP-1 receptor agonist; or, the medicament is a medicament for treating diseases mediated by the GLP-1R receptor; or, the medicament is a medicament for treating diabetes, overweight or obesity, liver disease, or Alzheimer's disease; or, the medicament is a medicament for treating non-alcoholic fatty liver disease or fatty liver disease associated with metabolic dysfunction, non-alcoholic steatohepatitis, or fatty liver disease associated with metabolic dysfunction; or, the medicament is a medicament for treating type 2 diabetes.
15. A kit or medicine box comprising the pharmaceutical composition as described in any one of claims 7-13.
